All In Biotech

Drug Trial Radar · NCT04831541

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 10, 2020

Primary completion

Dec 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
First Affiliated Hospital of Fujian Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the potential usefulness of 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions, efficacy assessment and recurrence monitoring in various types of cancer.

Conditions

  • Prostate Cancer
  • Positron-Emission Tomography

Interventions

  • 68Ga-PSMA-11Drug

    Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Standardized uptake value (SUV)Time frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.